FilingSEC EDGAR8-K
Outlook Therapeutics Sets Wholesale Acquisition Cost for LYTENAVATM at $485 per Vial
· SEC accepted
StageCommercialization
Filing content
Outlook Therapeutics announced that it has established the wholesale acquisition cost for LYTENAVATM in the United States at $485 per vial.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…